Wednesday that it would withdraw its COVID-19 vaccine Vaxzevria worldwide, weeks after withdrawing the vaccine’s European Union marketing authorization. An AstraZeneca statement provided to news outlets said: “As multiple, variant COVID-19 vaccines have since been developed, there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.” its application for FDA approval for the vaccine in 2022.
The company said it would proceed to withdraw Vaxzevria's marketing authorizations within Europe. The vaccine was never approved in the U.S. by the FDA.AstraZeneca has begun the worldwide withdrawal of its Covid-19 vaccine due to a “surplus of available updated vaccines” that target new variants of the virus.
On 7 May, the European Medicines Agency issued a notice that the vaccine is no longer authorised for use. "As multiple, variant COVID-19 vaccines have since been developed, there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied," various media outlets quoted the company was quoted as saying.